Safety and Efficacy of Camostat Mesylate for Covid-19: a systematic review and Meta-analysis of Randomized controlled trials.
Analysis
Camostat Mesylate
Covid-19
Pandemic
Review
SARS-CoV-2
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
19 Jul 2024
19 Jul 2024
Historique:
received:
22
10
2023
accepted:
03
06
2024
medline:
20
7
2024
pubmed:
20
7
2024
entrez:
19
7
2024
Statut:
epublish
Résumé
Camostat mesylate, an oral serine protease inhibitor, is a powerful TMPRSS2 inhibitor and has been reported as a possible antiviral treatment against COVID-19. Therefore, we aim to assess the safety and efficacy of camostat mesylate for COVID-19 treatment. A systematic review and meta-analysis synthesizing randomized controlled trials from PubMed, Scopus, Embase, Cochrane, Web of Science, clinical trials.gov, and medrxiv until June 2023. The outcomes were pooled using Mean difference (MD) for continuous outcomes and risk ratio (RR) for dichotomous outcomes. The protocol is registered in PROSPERO with ID CRD42023439633. Nine RCTs, including 1,623 patients, were included in this analysis. There was no difference between camostat mesylate and placebo in producing negative PCR test results at 1-7 days (RR: 0.76, 95% CI: [0.54, 1.06] P = 0.1), 8-14 days (RR: 1.02, 95% CI: [0.84, 1.23] P = 0.87), or 15-21 days (RR: 0.99, 95% CI: [0.82, 1.19] P = 0.90); clinical resolution of symptoms at 1-7 days (RR: 0.94 (95% CI: 0.58, 1.53) P = 0.81), 8-14 days (RR: 0.91, 95% CI: [0.74, 1.11] P = 0.33, ), or 15-21 days (RR: 0.77, 95% CI: [0.40, 1.51] P = 0.45); and time to symptom improvement (MD:-0.38 weeks (95% CI: [-1.42, 0.66] P = 0.47, I Camostat mesylate did not improve clinical outcomes in patients with COVID-19, compared to placebo.
Sections du résumé
BACKGROUND
BACKGROUND
Camostat mesylate, an oral serine protease inhibitor, is a powerful TMPRSS2 inhibitor and has been reported as a possible antiviral treatment against COVID-19. Therefore, we aim to assess the safety and efficacy of camostat mesylate for COVID-19 treatment.
METHODS
METHODS
A systematic review and meta-analysis synthesizing randomized controlled trials from PubMed, Scopus, Embase, Cochrane, Web of Science, clinical trials.gov, and medrxiv until June 2023. The outcomes were pooled using Mean difference (MD) for continuous outcomes and risk ratio (RR) for dichotomous outcomes. The protocol is registered in PROSPERO with ID CRD42023439633.
RESULTS
RESULTS
Nine RCTs, including 1,623 patients, were included in this analysis. There was no difference between camostat mesylate and placebo in producing negative PCR test results at 1-7 days (RR: 0.76, 95% CI: [0.54, 1.06] P = 0.1), 8-14 days (RR: 1.02, 95% CI: [0.84, 1.23] P = 0.87), or 15-21 days (RR: 0.99, 95% CI: [0.82, 1.19] P = 0.90); clinical resolution of symptoms at 1-7 days (RR: 0.94 (95% CI: 0.58, 1.53) P = 0.81), 8-14 days (RR: 0.91, 95% CI: [0.74, 1.11] P = 0.33, ), or 15-21 days (RR: 0.77, 95% CI: [0.40, 1.51] P = 0.45); and time to symptom improvement (MD:-0.38 weeks (95% CI: [-1.42, 0.66] P = 0.47, I
CONCLUSION
CONCLUSIONS
Camostat mesylate did not improve clinical outcomes in patients with COVID-19, compared to placebo.
Identifiants
pubmed: 39030491
doi: 10.1186/s12879-024-09468-w
pii: 10.1186/s12879-024-09468-w
doi:
Substances chimiques
camostat
0FD207WKDU
Antiviral Agents
0
Guanidines
0
Gabexate
4V7M9137X9
Serine Proteinase Inhibitors
0
Esters
0
Types de publication
Journal Article
Systematic Review
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Pagination
709Informations de copyright
© 2024. The Author(s).
Références
Khan S et al. Emergence of a novel coronavirus, severe Acute Respiratory Syndrome Coronavirus 2: Biology and Therapeutic options. J Clin Microbiol, 2020. 58(5).
Deslandes A, et al. SARS-CoV-2 was already spreading in France in late December 2019. Int J Antimicrob Agents. 2020;55(6):106006.
doi: 10.1016/j.ijantimicag.2020.106006
pubmed: 32371096
pmcid: 7196402
Lake MA. What we know so far: COVID-19 current clinical knowledge and research. Clin Med (Lond). 2020;20(2):124–7.
doi: 10.7861/clinmed.2019-coron
pubmed: 32139372
Beigel JH, et al. Remdesivir for the treatment of Covid-19 - final report. N Engl J Med. 2020;383(19):1813–26.
doi: 10.1056/NEJMoa2007764
pubmed: 32445440
Goldman JD, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med. 2020;383(19):1827–37.
doi: 10.1056/NEJMoa2015301
pubmed: 32459919
Horby P, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693–704.
doi: 10.1056/NEJMoa2021436
pubmed: 32678530
Spinner CD, et al. Effect of Remdesivir vs Standard Care on Clinical Status at 11 days in patients with moderate COVID-19: a Randomized Clinical Trial. JAMA. 2020;324(11):1048–57.
doi: 10.1001/jama.2020.16349
pubmed: 32821939
Johnson RM, Vinetz JM. Dexamethasone in the management of covid – 19. BMJ. 2020;370:m2648.
doi: 10.1136/bmj.m2648
pubmed: 32620554
Verderese JP, et al. Neutralizing monoclonal antibody treatment reduces hospitalization for mild and moderate coronavirus Disease 2019 (COVID-19): a real-world experience. Clin Infect Dis. 2022;74(6):1063–9.
doi: 10.1093/cid/ciab579
pubmed: 34166513
Kreutzberger AJB, et al. Synergistic block of SARS-CoV-2 infection by Combined Drug Inhibition of the host entry factors PIKfyve kinase and TMPRSS2 protease. J Virol. 2021;95(21):e0097521.
doi: 10.1128/JVI.00975-21
pubmed: 34406858
Hoffmann M, et al. Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity. EBioMedicine. 2021;65:103255.
doi: 10.1016/j.ebiom.2021.103255
pubmed: 33676899
pmcid: 7930809
Hoffmann M et al. Nafamostat Mesylate blocks activation of SARS-CoV-2: New Treatment option for COVID-19. Antimicrob Agents Chemother, 2020. 64(6).
Motoo Y. Antiproteases in the treatment of chronic pancreatitis. Jop. 2007;8(4 Suppl):533–7.
pubmed: 17625311
Page MJ, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
doi: 10.1136/bmj.n71
pubmed: 33782057
pmcid: 8005924
McKeown S, Mir ZM. Considerations for conducting systematic reviews: evaluating the performance of different methods for de-duplicating references. Syst Rev. 2021;10(1):38.
doi: 10.1186/s13643-021-01583-y
pubmed: 33485394
pmcid: 7827976
Higgins JP, et al. The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
doi: 10.1136/bmj.d5928
pubmed: 22008217
pmcid: 3196245
Guyatt GH, et al. What is quality of evidence and why is it important to clinicians? BMJ. 2008;336(7651):995–8.
doi: 10.1136/bmj.39490.551019.BE
pubmed: 18456631
pmcid: 2364804
Guyatt GH, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–6.
doi: 10.1136/bmj.39489.470347.AD
pubmed: 18436948
pmcid: 2335261
Cochrane Consumers and Communication, https:// cccrg.cochrane.org/author-resources
Reyman J. Book review: St.amant, Kirk, & Zemliansky, Pavel, editors. (2005). internet-based workplace communications: Industry and academic applications. hershey, PA: Information science publishing. Journal of Business and Technical Communication. 2007;21(4):442–5. doi:10.1171.
Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions 2008.
Chupp G, et al. A phase 2 Randomized, Double-Blind, placebo-controlled trial of oral Camostat Mesylate for Early Treatment of COVID-19 outpatients showed shorter illness course and attenuation of loss of smell and taste. medRxiv; 2022.
Jilg N, et al. One week of oral Camostat Versus Placebo in Nonhospitalized adults with mild-to-moderate coronavirus Disease 2019: a randomized controlled phase 2 trial. Clin Infect Dis. 2023;77(7):941–9.
doi: 10.1093/cid/ciad342
pubmed: 37279602
pmcid: 10552586
Tobback E, et al. Efficacy and safety of camostat mesylate in early COVID-19 disease in an ambulatory setting: a randomized placebo-controlled phase II trial. Int J Infect Dis. 2022;122:628–35.
doi: 10.1016/j.ijid.2022.06.054
pubmed: 35803469
pmcid: 9254441
Kinoshita T, et al. A multicenter, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of camostat mesilate in patients with COVID-19 (CANDLE study). BMC Med. 2022;20(1):342.
doi: 10.1186/s12916-022-02518-7
pubmed: 36163020
pmcid: 9512971
Gunst JD, et al. Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial. EClinicalMedicine. 2021;35:100849.
doi: 10.1016/j.eclinm.2021.100849
pubmed: 33903855
pmcid: 8060682
Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT) clinicaltrials.gov https://classic.clinicaltrials.gov/ct2/history/NCT04583592?V_9=View .
Kim YS, et al. A Double-Blind, randomized, Placebo-Controlled, phase II clinical study to evaluate the efficacy and safety of Camostat Mesylate (DWJ1248) in adult patients with mild to moderate COVID-19. Antimicrob Agents Chemother. 2023;67(1):e0045222.
doi: 10.1128/aac.00452-22
pubmed: 36515544
Karolyi M, et al. Camostat Mesylate Versus Lopinavir/Ritonavir in hospitalized patients with COVID-19-Results from a Randomized, controlled, open label, platform trial (ACOVACT). Front Pharmacol. 2022;13:870493.
doi: 10.3389/fphar.2022.870493
pubmed: 35935856
pmcid: 9354138
Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients (COPS-2003) clinicaltrials gov https://classic.clinicaltrials.gov/ct2/show/NCT04524663 .
Amani B, Amani B. Efficacy and safety of nirmatrelvir/ritonavir (paxlovid) for COVID-19: a rapid review and meta-analysis. J Med Virol. 2023;95(2):e28441.
doi: 10.1002/jmv.28441
pubmed: 36576379
pmcid: 9880713
Tian H, et al. Efficacy and safety of paxlovid (nirmatrelvir/ritonavir) in the treatment of COVID-19: an updated meta-analysis and trial sequential analysis. Rev Med Virol. 2023;33(5):e2473.
doi: 10.1002/rmv.2473
pubmed: 37485774
Hoffmann M et al. Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity. bioRxiv, 2020.
Abuelazm M, et al. The Effect of Nitazoxanide on the clinical outcomes in patients with COVID-19: a systematic review and Meta-analysis of Randomized controlled trials. Clin Drug Investig. 2022;42(12):1031–47.
doi: 10.1007/s40261-022-01213-y
pubmed: 36315350
pmcid: 9628625
Breining P, et al. Camostat mesylate against SARS-CoV-2 and COVID-19-Rationale, dosing and safety. Basic Clin Pharmacol Toxicol. 2021;128(2):204–12.
doi: 10.1111/bcpt.13533
pubmed: 33176395
Li K, et al. The TMPRSS2 inhibitor Nafamostat reduces SARS-CoV-2 Pulmonary infection in mouse models of COVID-19. mBio. 2021;12(4):e0097021.
doi: 10.1128/mBio.00970-21
pubmed: 34340553
Reuter N et al. SARS-CoV-2 spike protein is capable of inducing cell-cell fusions independent from its receptor ACE2 and this activity can be impaired by furin inhibitors or a subset of monoclonal antibodies. Viruses, 2023. 15(7).
Koch J, et al. TMPRSS2 expression dictates the entry route used by SARS-CoV-2 to infect host cells. Embo j. 2021;40(16):e107821.
doi: 10.15252/embj.2021107821
pubmed: 34159616
pmcid: 8365257
Meng B, et al. Altered TMPRSS2 usage by SARS-CoV-2 omicron impacts infectivity and fusogenicity. Nature. 2022;603(7902):706–14.
doi: 10.1038/s41586-022-04474-x
pubmed: 35104837
pmcid: 8942856
Ortiz-Fernández L, Sawalha AH. Genetic variability in the expression of the SARS-CoV-2 host cell entry factors across populations. Genes Immun. 2020;21(4):269–72.
doi: 10.1038/s41435-020-0107-7
pubmed: 32759995
pmcid: 7484169
Li F, et al. Distinct mechanisms for TMPRSS2 expression explain organ-specific inhibition of SARS-CoV-2 infection by enzalutamide. Nat Commun. 2021;12(1):866.
doi: 10.1038/s41467-021-21171-x
pubmed: 33558541
pmcid: 7870838
Maekawa A, et al. Camostat mesilate inhibits prostasin activity and reduces blood pressure and renal injury in salt-sensitive hypertension. J Hypertens. 2009;27(1):181–9.
doi: 10.1097/HJH.0b013e328317a762
pubmed: 19145783
Yuan L, et al. Camostat mesilate inhibits pro-inflammatory cytokine secretion and improves cell viability by regulating MFGE8 and HMGN1 in lipopolysaccharide-stimulated DF-1 chicken embryo fibroblasts. PeerJ. 2021;9:e12053.
doi: 10.7717/peerj.12053
pubmed: 34527443
pmcid: 8403478
Kastenhuber ER et al. Coagulation factors directly cleave SARS-CoV-2 spike and enhance viral entry. Elife, 2022. 11.
Zhao J, et al. A protease inhibitor against acute stress-induced visceral hypersensitivity and paracellular permeability in rats. Eur J Pharmacol. 2011;654(3):289–94.
doi: 10.1016/j.ejphar.2010.12.032
pubmed: 21237151
Assylbekova A, et al. Camostat does not inhibit the proteolytic activity of Neutrophil Serine proteases. Volume 15. Pharmaceuticals (Basel); 2022. 5.